Editorial |

Treatment of Alzheimer Disease and Prognosis of Dementia:  Time to Translate Research to Results

Kristine Yaffe, MD
JAMA. 2010;304(17):1952-1953. doi:10.1001/jama.2010.1625.
Text Size: A A A
Published online


In this issue of JAMA, 2 studies address the treatment and prognosis of patients with dementia. Quinn and colleagues1 describe results from a well-conducted trial conducted in conjunction with the Alzheimer's Disease Cooperative Study (ADCS) network designed to determine if treatment with the omega-3 fatty acid docosahexaenoic acid (DHA) improved the symptoms and course of patients with mild to moderate Alzheimer disease (AD). The multisite trial enrolled 402 patients (60% were assigned to DHA and 40% to placebo). At the end of the 18-month trial, there were no treatment group differences on any of the primary or secondary outcomes despite elevations of plasma phospholipids and cerebrospinal fluid DHA (measured in a subgroup). Among the 102 participants with baseline and follow-up brain magnetic resonance imaging, there were also no effects of treatment on total brain or hippocampal volume changes. However, among patients without an apolipoprotein E (APOE) ε4 allele, those assigned to DHA had less decline compared with those receiving placebo on 1 primary outcome and 1 secondary outcome.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 5

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario